What's hold­ing back biotech M&A? SVB tracks a trend and calls a come­back

Jon Nor­ris, SVB

The deal­mak­ers in bio­phar­ma have had some ex­tra time on their hands in the first half of 2017. M&A has slowed con­sid­er­ably, but one promi­nent play­er in the field is keep­ing the faith that H2 will make up for the lag.

Sil­i­con Val­ley Bank has put out its re­port on the first half of the year, and you can see from the chart be­low — which com­bines biotech IPOs and M&A — what I mean by a slow­down.

IPOs con­tin­ue to chug along, with 15 in the first half and a queue that will prob­a­bly con­tin­ue to de­liv­er at a rate that will end up slight­ly high­er than 2016, says SVB. That’s not a 2014-style boom, but it’s a nice, steady pace that is con­tin­u­ing to pump hun­dreds of mil­lions of dol­lars in­to the in­dus­try. But with sev­en M&A deals to con­sid­er in H1, buy­ers are go­ing to have to dou­ble down in the sec­ond half to make up the short­fall.

I talked about the deal pace with SVB’s Jon Nor­ris at a biotech  pan­el I mod­er­at­ed in San Fran­cis­co a few months ago. And I asked him to add his thoughts on what’s dri­ving the slow­down in M&A and why he thinks there will be a bump in deals in the six months to come.

Bot­tom line: More mon­ey com­ing through VCs and IPOs con­tin­ues to pro­vide the best pay­back for in­vestors. Nor­ris notes:

Yes, M&A is be­hind in the first half of 2017 but we do hear sig­nif­i­cant chat­ter about in-progress deal dis­cus­sions and think that year-end 2017 num­bers will end up around 20.  So pent up de­mand is one an­swer — big bio­phar­ma has not changed its out­sourc­ing of re­search to ven­ture-backed com­pa­nies. They will con­tin­ue to buy these com­pa­nies to add to their pipeline.

One the­o­ry around why M&A is low in the first half re­lates to liq­uid­i­ty and pub­lic mar­ket ac­cess. First, we have seen a change in fi­nanc­ing over the last few years, with round sizes that are his­tor­i­cal­ly high (many $50M+ tranched fi­nanc­ings), and de­signed to last longer (3-4 years). The cur­rent crop of these com­pa­nies has sig­nif­i­cant dry pow­der to de­vel­op their tech­nol­o­gy and ad­vance clin­i­cal tri­als. Sec­ond, the IPO win­dow con­tin­ues to stay open and crossovers pre­fer IPO to M&A. Crossover in­vestors have made a sig­nif­i­cant num­ber of in­vest­ments in these pri­vate com­pa­nies. Crossovers pre­fer to take com­pa­nies pub­lic (so they can dou­ble down on their ini­tial in­vest­ment), so many of these com­pa­nies are push­ing to­wards IPOs.  Thus, with sig­nif­i­cant dry pow­der from these large pri­vate fi­nanc­ings and ex­pec­ta­tions to IPO, these com­pa­nies can af­ford to be pa­tient. That said — we do, how­ev­er, ex­pect ex­its to in­crease in the sec­ond half.

An­swer­ing a query on val­u­a­tions in biotech, Nor­ris al­so says he’s see­ing a shift to­ward some­what lat­er-stage ex­its in the months to come.

Re­gard­less of the val­u­a­tion, the his­tor­i­cal mul­ti­ple on in­vest­ed cap­i­tal ex­pec­ta­tions for ex­it­ing on Pre-Clin­i­cal da­ta doesn’t match com­pa­nies who have raised a large fi­nanc­ing round.  As an ex­am­ple, the fif­teen ven­ture-backed pre-clin­i­cal ex­its since 2014 had a me­di­an up-front deal val­ue of $180m with a me­di­an in­vest­ed cap­i­tal at $30 and me­di­an up-front mul­ti­ple on cap­i­tal-in­vest­ed of 7.3X.  The big $50M+ fi­nanc­ings make it hard­er to ac­cept ear­ly of­fers, but on the oth­er hand these com­pa­nies have enough cap­i­tal to get fur­ther down the de­vel­op­ment path.  That is why we are see­ing slight­ly lat­er stage ex­its in 2017, and think that trend will con­tin­ue.

The oth­er point that I want to high­light is where the deals are be­ing made in the in­dus­try. As I not­ed in Tues­day’s re­port, on­col­o­gy has emerged as clear­ly the hottest re­search field, way ahead of the rest of the pack as im­muno-on­col­o­gy con­tin­ues to dri­ve bil­lions in new in­vest­ments. So it’s no great sur­prise to see can­cer lead­ing the pack of in­di­ca­tions on M&A and IPOs over the last 2.5 years. Neu­ro and or­phan/rare dis­eases come in tied for sec­ond place. Aes­thet­ics/derm, car­dio­vas­cu­lar and meta­bol­ics round out the pack.

 

At the In­flec­tion Point for the Next Gen­er­a­tion of Can­cer Im­munother­a­py

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.

All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at FDA; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

The slate of products we’re offering here at Endpoints is continuing to grow, and it’s not just limited to editorial. If you haven’t, do visit your reader profile to see if there are any other weekly newsletters you’re interested in — as each comes with its own exclusive content. And don’t miss the publisher’s note from Arsalan Arif on Endpoints Studio, our latest avenue for advertising on Endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Usama Malik

Ex-Im­munomedics CFO charged with in­sid­er trad­ing, faces up to 20 years in prison af­ter al­leged­ly tip­ping off girl­friend and rel­a­tives of a PhI­II suc­cess

The former CFO of Immunomedics, who helped steer the company to its $21 billion buyout by Gilead last year, has been charged with insider trading, the Department of Justice announced Thursday.

Usama Malik tipped off his then-girlfriend and four others that a Phase III study for Trodelvy would be stopped early four days before Immunomedics publicly announced the result in April 2020, DoJ alleged in its complaint. The individuals then purchased Immunomedics shares, selling them after the news broke and Immunomedics’ stock price doubled.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Merck's new antiviral molnupiravir (Quality Stock Arts / Shutterstock)

As Omi­cron spread looms, oral an­tivi­rals ap­pear to be one of the best de­fens­es — now we just need more

After South African scientists reported a new Covid-19 variant — dubbed Omicron by the WHO — scientists became concerned about how effective vaccines and monoclonal antibodies might be against it, which has more than 30 mutations in the spike protein.

“I think it is super worrisome,” Dartmouth professor and Adagio co-founder and CEO Tillman Gerngross told Endpoints News this weekend. Moderna CEO Stéphane Bancel echoed similar concerns, telling the Financial Times that experts warned him, “This is not going to be good.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie tacks on a new warn­ing to Rin­voq la­bel as safe­ty frets crimp JAK class

The safety problems that continue to plague the JAK class as new data highlight some severe side effects are casting a large shadow over AbbVie’s Rinvoq.

As a result of a recent readout highlighting major adverse cardiac events (MACE), malignancy, mortality and thrombosis with Xeljanz a couple of months ago, AbbVie put out a notice late Friday afternoon that it is adding the new class risks to its label for their rival drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Biospec­i­men M&A: Dis­cov­ery ac­quires Al­bert Li's he­pa­to­cyte project; PhI­II tri­al on Bay­er's Nube­qa reached pri­ma­ry end­point

Discovery Life Sciences has acquired what claims to be the Maryland-based host of the world’s largest hepatocyte inventory, known as IVAL, to help researchers select more effective and safer drug candidates in the future.

The combined companies will now serve a wider range of drug research and development scientists, according to Albert Li, who founded IVAL in 2004 and is set to join the Discovery leadership team as the CSO of pharmacology and toxicology.

Pfiz­er, Am­gen and Janssen seek fur­ther clar­i­ty on FDA's new ben­e­fit-risk guid­ance

Three top biopharma companies are seeking more details from the FDA on how the agency conducts its benefit-risk assessments for new drugs and biologics.

While Pfizer, Amgen and Janssen praised the agency for further spelling out its thinking on the subject in a new draft guidance, including a discussion of patient experience data as part of the assessment, the companies said the FDA could’ve included more specifics in the 20-page draft document.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Re­searchers move clos­er to de­ci­pher­ing blood clots from As­traZeneca, J&J's Covid-19 vac­cines

Researchers may be nearing an answer for the mysterious and life-threatening blood clots that appeared on very rare occasions in people who received the J&J or AstraZeneca Covid-19 vaccine.

The new work builds on an early hypothesis researchers in Norway put forward last spring, when the cases first cropped up. They proposed the events were similar to blood clots that can occur in a small subset of patients who receive heparin, one of the most commonly used blood thinners.

Janet Woodcock (AP Images)

Janet Wood­cock plots her fu­ture at FDA, with se­nior ad­vi­sor role to fall back on if Califf wins con­fir­ma­tion

Acting FDA commissioner Janet Woodcock has been the face of just about every drug approval decision at the agency since the turn of the century. Since the pandemic began, she’s moved between the top of the drugs center to the head of therapeutics at Operation Warp Speed, leading the drive for work on Covid-targeted mAbs and antivirals.

Looking forward — and pending a quick Senate confirmation to cement Rob Califf’s return to the top of FDA early next year — Woodcock’s role at the agency will again be in flux.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.